Iconovo
| Published November 4, 2024

Inhalation specialists Iconovo raises capital

An intranasal obesity treatment under development, a generic challenger to the asthma product Symbicort and talks with potential partners are on the agenda for Iconovo, which is also currently in the process of a rights issue of SEK 28,7 million.

Se Iconovos CEO, Johan Waborg, tell us about the latest developments.

BioStock is a news service and does not provide investment advice, does not mediate any investment orders and does not take any responsibility for actions and/or any loss or damage of any kind based on the use of content published on BioStock.se. Instead, each investment decision is made independently by the individual investor. The content of BioStock's news and analyses is independent, but as BioStock's operations are partly financed by companies in the industry, the BioStock website may contain news about companies from which BioStock has received funding.

This material has been prepared for marketing purposes and is not and shall not be considered to constitute a prospectus under applicable laws and regulations. The full terms of the rights issue and further information about the company have been set out in a memorandum which has been published and published on the website of the above-mentioned company.